dbo:abstract
|
- DMTHF-Tc (5N,10N-dimethyl tetrahydrofolic acid) is a radiopharmaceutical which combines DMTHF, a modified folate, with technetium-99m (99mTc), a gamma emitting radionuclide, in a chelate conjugate. It shows selectivity for certain cancer cells which overexpress FR-α, and can therefore be used for diagnostic imaging in nuclear medicine. DMTHF-Tc was developed by the Philip Low lab at Purdue University. DMTHF-Tc is a type of folate targeting, an imaging and drug delivery method where the folate receptor (FR), being upregulated on malignant and inflamed cell types, is targeted. It can be used to reduce drug toxicity, as well as to visualize or quantify the amount of disease in cancerous and inflamed tissue. In normal tissues, the FR shows limited distribution. However, in cancer cells, FR-α shows upregulation, while FR-β expression is increased in inflamed tissues on activated macrophages. Because the receptor has these two isoforms that are only 76% homologous, the isoforms can be selectively bound in different types of diseased tissue for folate targeting. (en)
|
rdfs:comment
|
- DMTHF-Tc (5N,10N-dimethyl tetrahydrofolic acid) is a radiopharmaceutical which combines DMTHF, a modified folate, with technetium-99m (99mTc), a gamma emitting radionuclide, in a chelate conjugate. It shows selectivity for certain cancer cells which overexpress FR-α, and can therefore be used for diagnostic imaging in nuclear medicine. DMTHF-Tc was developed by the Philip Low lab at Purdue University. (en)
|